

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-16. (Canceled)

17. (Withdrawn) A method of treating a condition related to resistance to cell death, comprising administering a substantially pure cytotoxic factor, or a variant or derivative thereof, optionally incorporated in a pharmaceutical carrier, to promote cell death in a cell demonstrating resistance to cell death.

18. (Withdrawn) The method of claim 17 wherein the condition related to resistance to cell death is selected from the group consisting of human melanoma, leukemia, breast cancer, ovarian cancer, lung cancer, mesenchymal cancer, colon cancer and aerodigestive tract cancers.

19. (Withdrawn) The method of claim 18 wherein the pharmaceutical carrier is selected from the group consisting of a filler, a cellulose preparation, a flavoring agent, a coloring agent, a thickener, a detackifier, an additive, a binder, an adjuvant, and mixtures thereof.

20. (Withdrawn) The method of claim 18 wherein the cytotoxic factor is administered orally, buccally, by inhalation, sublingually, rectally, vaginally, transurethrally, nasally, topically, or percutaneously.

21. (Withdrawn) A method of treating a condition related to cell death susceptibility, comprising the step of administering a therapeutically effective amount of an inhibitor of a cytotoxic factor, or a derivative thereof, optionally incorporated in a pharmaceutical carrier, to inhibit cell death in a cell demonstrating susceptibility to cell death.

22. (Withdrawn) The method of claim 21 wherein the inhibitor is selected from the group consisting of:

- (a) an active agent that inhibits secretion of an ATP-utilizing enzyme,
- (b) an active agent that inhibits the cytotoxic activity of an ATP-utilizing enzyme,
- (c) an active agent that inhibits secretion of a redox protein, and
- (d) an active agent that inhibits the cytotoxic activity of a redox protein.

23. (Currently amended) A method comprising administering to a patient a pharmaceutical composition comprising a compound selected from the group consisting of azurin or a cytotoxic factor, and a variant or derivative thereof and cytochrome C₅₅₁ or a variant or derivative thereof of the cytotoxic factor; wherein the compound modulates cell death in the patient.

24. (Canceled)

25. (Canceled)

26. (Previously Presented) The method of claim 23, wherein the cytotoxic factor is azurin or cytochrome C₅₅₁.

27. (Previously Presented) The method of claim 26, wherein the cytotoxic factor is azurin.

28. (Previously Presented) The method of claim 26, wherein the cytotoxic factor is cytochrome C₅₅₁.

29. (Canceled)

30. (Currently amended) The method of claim 23 ~~29~~, wherein the compound is azurin or a variant or derivative thereof.

31. (Currently amended) The method of claim 23 ~~29~~, wherein the compound is cytochrome C₅₅₁ or a variant or derivative thereof.

32. (Currently amended) The method of claim 30 ~~29~~, wherein the compound is *Pseudomonas aeruginosa* azurin or a variant or derivative thereof.

33. (Previously Presented) The method of claim 23, wherein the compound increases cell death in the patient.

34. (Previously Presented) The method of claim 23, wherein the compound increases cell death of cancer cells in the patient.

35. (Previously Presented) The method of claim 34, wherein the cancer cells are selected from the group consisting of melanoma cells, leukemia cells, breast cancer cells, ovarian cancer cells, lung cancer cells, mesenchymal cancer cells, colon cancer cells, and aerodigestive tract cancer cells.

36. (Previously Presented) The method of claim 35, wherein the cancer cells are melanoma cells.

37. (Previously Presented) The method of claim 23, wherein the compound increases cell apoptosis in the patient.

38. (Currently amended) The method of claim 23, wherein the pharmaceutical composition comprises azurin or a variant or derivative thereof and cytochrome C₅₅₁ or a variant or derivative thereof.

39. (Previously Presented) The method of claim 23, wherein the pharmaceutical composition further comprises a pharmaceutical carrier.

40. (Currently amended) A method comprising contacting cells with a compound selected from the group consisting of ~~a cytotoxic factor~~, azurin or a variant or derivative thereof and cytochrome C₅₅₁ or a variant or derivative thereof ~~of the cytotoxic factor~~; wherein the compound inhibits growth of the cells and wherein the cells are cancer cells.

41. (Canceled)

42. (Currently amended) The method of claim 40 41, wherein the cytotoxic factor is azurin or cytochrome C₅₅₁.

43. (Previously Presented) The method of claim 42, wherein the compound kills the cells.

44. (Currently amended) The method of claim 40 41, wherein the compound increases apoptosis of the cells.

45. (Canceled)

46. (Previously Presented) The method of claim 42, wherein the cytotoxic factor is azurin.

47. (Previously Presented) The method of claim 46, further comprising contacting the cells with cytochrome C₅₅₁ or a variant or derivative thereof.

48. (Previously Presented) The method of claim 42, wherein the cytotoxic factor is cytochrome C₅₅₁.

49. (New) The method of claim 44, wherein the cells are melanoma cells.

50. (New) The method of claim 40, wherein the cells are selected from the group consisting of melanoma cells, leukemia cells, breast cancer cells, ovarian cancer cells, lung cancer cells, mesenchymal cancer cells, colon cancer cells, and aerodigestive tract cancer cells.